Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

ANI Pharma Inc (ANIP)

ANI Pharma Inc (ANIP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,212,868
  • Shares Outstanding, K 20,973
  • Annual Sales, $ 486,820 K
  • Annual Income, $ 18,780 K
  • 60-Month Beta 0.71
  • Price/Sales 2.45
  • Price/Cash Flow 8.96
  • Price/Book 2.65
Trade ANIP with:

Options Overview Details

View History
  • Implied Volatility 42.34% ( +2.25%)
  • Historical Volatility 41.03%
  • IV Percentile 74%
  • IV Rank 63.90%
  • IV High 53.78% on 10/27/23
  • IV Low 22.09% on 11/17/23
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 625
  • Open Int (30-Day) 596

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.74
  • Number of Estimates 4
  • High Estimate 0.79
  • Low Estimate 0.68
  • Prior Year 1.05
  • Growth Rate Est. (year over year) -29.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.53 +10.09%
on 09/11/24
63.72 -9.24%
on 09/05/24
-5.11 (-8.12%)
since 09/04/24
3-Month
52.53 +10.09%
on 09/11/24
66.51 -13.05%
on 07/31/24
-2.99 (-4.92%)
since 07/03/24
52-Week
48.20 +19.98%
on 12/08/23
70.81 -18.33%
on 03/25/24
+0.34 (+0.59%)
since 10/04/23

Most Recent Stories

More News
Pacira's Exparel Receives Permanent New Product-Specific J-Code

Pacira BioSciences PCRX announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code (J0666) for its lead pain-management drug, Exparel (bupivacaine...

KRYS : 177.11 (+0.67%)
FULC : 3.82 (+4.23%)
ANIP : 57.83 (+1.83%)
PCRX : 16.51 (+3.93%)
Zevra Stock Surges Close to 70% in 3 Months: Here's Why

Zevra Therapeutics, Inc. ZVRA obtained FDA approval for arimoclomol capsules for the treatment of Niemann-Pick disease type C (NPC) in September. The drug will be marketed under the brand name Miplyffa.The...

ZVRA : 7.20 (+0.28%)
KRYS : 177.11 (+0.67%)
FULC : 3.82 (+4.23%)
ANIP : 57.83 (+1.83%)
RARE's Wilson Disease Candidate Betters Standard Therapy in Study

Ultragenyx Pharmaceutical RARE reported positive updates from the Stage 1 cohorts of its phase I/II/III Cyprus2+ study evaluating UX701, an investigational AAV9 gene therapy, to treat Wilson disease. Stage...

KRYS : 177.11 (+0.67%)
RARE : 53.79 (+0.24%)
FULC : 3.82 (+4.23%)
ANIP : 57.83 (+1.83%)
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag

Ionis Pharmaceuticals, Inc. IONS announced that the FDA has granted a Fast Track designation to its investigational RNA-targeted therapy zilganersen for treating Alexander disease (AxD), an ultra-rare...

KRYS : 177.11 (+0.67%)
FULC : 3.82 (+4.23%)
IONS : 37.91 (+0.26%)
ANIP : 57.83 (+1.83%)
Here's Why Investors Should Consider Buying Corcept Stock Now

Corcept Therapeutics’ CORT sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing strong demand in the past...

CORT : 45.43 (+0.87%)
KRYS : 177.11 (+0.67%)
ANIP : 57.83 (+1.83%)
BVS : 11.75 (+0.69%)
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims

Cassava Sciences SAVA has agreed to pay a $40 million fine to settle charges from the U.S. Securities and Exchange Commission (SEC) over allegedly misleading statements about the results of its 2020 mid-stage...

KRYS : 177.11 (+0.67%)
FULC : 3.82 (+4.23%)
ANIP : 57.83 (+1.83%)
SAVA : 27.08 (+0.45%)
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies

Shares of Biomea Fusion BMEA gained 9.1% on Thursday after the FDA lifted the clinical hold it had earlier placed on the company’s ongoing early to mid-stage studies evaluating its lead candidate, BMF-219,...

KRYS : 177.11 (+0.67%)
FULC : 3.82 (+4.23%)
BMEA : 10.48 (+3.87%)
ANIP : 57.83 (+1.83%)
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study

Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study of its investigational candidate, barzolvolimab, which is being developed for...

CLDX : 30.65 (-0.62%)
KRYS : 177.11 (+0.67%)
FULC : 3.82 (+4.23%)
ANIP : 57.83 (+1.83%)
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals

Roche RHHBY announced positive top-line data from a late-stage study of its marketed drug, Gazyva/Gazyvaro (obinutuzumab), to treat patients with active lupus nephritis (LN). The phase III REGENCY study...

KRYS : 177.11 (+0.67%)
FULC : 3.82 (+4.23%)
ANIP : 57.83 (+1.83%)
RHHBY : 37.7700 (-1.33%)
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study

Shares of Wave Life Sciences WVE surged 53.4% on Tuesday after the company announced positive interim data from a mid-stage study evaluating its investigational candidate, WVE-N531, to treat boys with...

KRYS : 177.11 (+0.67%)
WVE : 8.41 (-1.06%)
FULC : 3.82 (+4.23%)
ANIP : 57.83 (+1.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone...

See More

Key Turning Points

3rd Resistance Point 59.13
2nd Resistance Point 58.72
1st Resistance Point 58.27
Last Price 57.83
1st Support Level 57.41
2nd Support Level 57.00
3rd Support Level 56.55

See More

52-Week High 70.81
Fibonacci 61.8% 62.17
Fibonacci 50% 59.50
Last Price 57.83
Fibonacci 38.2% 56.84
52-Week Low 48.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar